Literature DB >> 1865082

Insulin-like growth factor I: a good indicator of functional hepatocellular capacity in alcoholic liver cirrhosis.

A Caufriez1, P Reding, D Urbain, J Golstein, G Copinschi.   

Abstract

To assess the value of serum insulin-like growth factor I (IGF-I) determination in liver disease, 21 patients hospitalized for active alcoholic cirrhosis (19 males, 2 females), 56 +/- 2 y (mean +/- SE) were studied at admission. Individual scores of hepatic alterations (Child score) ranged from 6 to 12 (mean: 9 +/- 1). Basal IGF-I levels were dramatically decreased, averaging 0.11 +/- 0.02 U/ml vs 0.70 +/- 0.08 U/ml in 15 control subjects. In cirrhotic patients, IGF-I values were inversely correlated with the modified Child index (r = 0.57, p less than 0.01). A highly significant positive correlation (r = 0.68, p less than 0.001) was evidenced between IGF-I levels and aminopyrine breath test values (which provide quantitative estimates of the hepatic functional capacity). In contrast, no significant relationship was found between IGF-I levels and various nutritional parameters (albumin, prealbumin, retinol binding protein) after partial correlation analysis. The present data suggest that, in alcoholic cirrhosis, the decrease of circulating IGF-I values is mainly related to alterations of liver function, and that IGF-I can be used as a good indicator of functional hepatocellular capacity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1865082     DOI: 10.1007/BF03346823

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

2.  Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia.

Authors:  J C Wu; W H Daughaday; S D Lee; T S Hsiao; C K Chou; H D Lin; Y T Tsai; B N Chiang
Journal:  J Lab Clin Med       Date:  1988-11

3.  Regulation of somatomedin-C/insulin-like growth factor I by nutrients.

Authors:  L E Underwood; D R Clemmons; M Maes; A J D'Ercole; J M Ketelslegers
Journal:  Horm Res       Date:  1986

4.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

5.  Somatomedin production in normal adults and cirrhotic patients.

Authors:  R M Schimpff; D Lebrec; M Donnadieu
Journal:  Acta Endocrinol (Copenh)       Date:  1977-10

6.  Growth hormone hyperresponsiveness to growth hormone-releasing hormone in patients with severe liver cirrhosis.

Authors:  F Salerno; V Locatelli; E E Müller
Journal:  Clin Endocrinol (Oxf)       Date:  1987-08       Impact factor: 3.478

7.  Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat.

Authors:  B H Lauterburg; J Bircher
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

8.  In vivo and in vitro effect of liver on somatomedin generation.

Authors:  F Minuto; A Barreca; P Del Monte; C Buffa; R Bevevino; F Montale; G Torre; G Giordano
Journal:  Horm Metab Res       Date:  1984-12       Impact factor: 2.936

Review 9.  Nutrition, somatomedins, and the brain.

Authors:  L S Phillips
Journal:  Metabolism       Date:  1986-01       Impact factor: 8.694

10.  Synthesis and secretion of insulin-like growth factor and its binding protein by the perfused rat liver: dependence on growth hormone status.

Authors:  J C Schwander; C Hauri; J Zapf; E R Froesch
Journal:  Endocrinology       Date:  1983-07       Impact factor: 4.736

View more
  15 in total

1.  Effect of IGF-I on total serum antioxidant status in cirrhotic rats.

Authors:  M García-Fernández; I Castilla-Cortázar; M Díaz-Sánchez; F Díez Caballero; A Castilla; A Díaz Casares; I Varela-Nieto; S González-Barón
Journal:  J Physiol Biochem       Date:  2003-06       Impact factor: 4.158

2.  Bone mineral density and disorders of mineral metabolism in chronic liver disease.

Authors:  Joe George; Hosahithlu K Ganesh; Shrikrishna Acharya; Tushar R Bandgar; Vyankatesh Shivane; Anjana Karvat; Shobna J Bhatia; Samir Shah; Padmavathy S Menon; Nalini Shah
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

3.  Hematotesticular barrier is altered from early stages of liver cirrhosis: effect of insulin-like growth factor 1.

Authors:  Inma Castilla-Cortazar; Nieves Diez; Maria Garcia-Fernandez; Juan-Enrique Puche; Fernando Diez-Caballero; Jorge Quiroga; Matias Diaz-Sanchez; Alberto Castilla; Amelia-Diaz Casares; Isabel Varela-Nieto; Jesus Prieto; Salvador Gonzalez-Baron
Journal:  World J Gastroenterol       Date:  2004-09-01       Impact factor: 5.742

4.  Mitochondrial protection by low doses of insulin-like growth factor- I in experimental cirrhosis.

Authors:  Raquel Pérez; María García-Fernández; Matías Díaz-Sánchez; Juan E Puche; Gloria Delgado; Marian Conchillo; Jordi Muntané; Inma Castilla-Cortázar
Journal:  World J Gastroenterol       Date:  2008-05-07       Impact factor: 5.742

Review 5.  Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors:  Juan E Puche; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2012-11-14       Impact factor: 5.531

6.  A survey of correlation between insulin-like growth factor-I (igf-I) levels and severity of liver cirrhosis.

Authors:  Asghar Khoshnood; Mohsen Nasiri Toosi; Mohammad Jafar Faravash; Alireza Esteghamati; Hosein Froutan; Hadi Ghofrani; Mohammad Kalani; Arash Miroliaee; Ahmad Abdollahi; Andrabi Yasir
Journal:  Hepat Mon       Date:  2013-02-23       Impact factor: 0.660

7.  Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells.

Authors:  Alessandra Gentilini; Benedetta Lottini; Marco Brogi; Alessandra Caligiuri; Lorenzo Cosmi; Fabio Marra; Massimo Pinzani
Journal:  Fibrogenesis Tissue Repair       Date:  2009-01-30

8.  Tumor necrosis factor alpha is involved in mouse growth and lymphoid tissue development.

Authors:  S de Kossodo; G E Grau; T Daneva; P Pointaire; L Fossati; C Ody; J Zapf; P F Piguet; R C Gaillard; P Vassalli
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

9.  Jejunal microvilli atrophy and reduced nutrient transport in rats with advanced liver cirrhosis: improvement by Insulin-like Growth Factor I.

Authors:  Inma Castilla-Cortázar; María Pascual; Elena Urdaneta; Javier Pardo; Juan Enrique Puche; Bárbara Vivas; Amelia Díaz-Casares; María García; Matías Díaz-Sánchez; Isabel Varela-Nieto; Alberto Castilla; Salvador González-Barón
Journal:  BMC Gastroenterol       Date:  2004-06-14       Impact factor: 3.067

10.  Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis.

Authors:  María García-Fernández; Inma Castilla-Cortázar; Matías Díaz-Sanchez; Iñigo Navarro; Juan Enrique Puche; Alberto Castilla; Amelia Díaz Casares; Encarna Clavijo; Salvador González-Barón
Journal:  BMC Gastroenterol       Date:  2005-03-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.